Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Myriad Genetics Study Shows RiskScore Doubles Accuracy in ⁤Predicting Breast Cancer Risk

SALT LAKE CITY, Dec. 19, 2024 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leading provider of genetic and genomic testing, announced groundbreaking results from a new study demonstrating the superior accuracy of its RiskScore® test in predicting breast cancer risk.⁤ The study, which compared RiskScore to the widely used Tyrer-Cuzick model, found that RiskScore doubled the accuracy in identifying women at increased risk for⁢ developing breast cancer.

“This study provides compelling evidence that⁣ RiskScore is a meaningful advancement in breast cancer risk assessment,” said [Insert Name and Title of Myriad Genetics Spokesperson]. “By accurately identifying women at higher risk,RiskScore empowers them and thier healthcare providers⁣ to make informed decisions about personalized‌ screening and prevention strategies.”

The study, which involved [Insert Number] participants, analyzed the‌ performance of ⁢both riskscore and the Tyrer-Cuzick model in predicting breast ⁤cancer incidence over a [Insert Time Period] period.The results showed ⁢that RiskScore correctly identified ‍ [Insert Percentage] of women who developed breast cancer, compared to [Insert Percentage] for the Tyrer-Cuzick ‍model.

This significant improvement in accuracy has​ the potential to revolutionize ⁣breast cancer screening and prevention. By identifying‌ high-risk individuals earlier, RiskScore can enable more targeted⁢ interventions, such as increased screening‌ frequency or prophylactic measures, ultimately leading to better outcomes for patients.

Myriad Genetics is committed​ to advancing the field of precision​ medicine through innovative genetic testing solutions. RiskScore represents a major step forward ‌in personalized healthcare, empowering⁢ individuals to take control of their breast health.

Hereditary Cancer Test Makes Waves in genomic Medicine

Myriad Genetics’ RiskScore ‍Test Recognized as a Top Advance in Genomic Medicine

A groundbreaking study on Myriad Genetics’ Hereditary Cancer Test ⁢with RiskScore® has been ⁤named one of the American Journal of Human Genetics’ top 10 significant advances in genomic medicine. The prestigious recognition comes from the‌ Genomic Medicine Working Group at the National Human Genome Research Institute.

The study, led by Mabey et al., titled “Validation of a clinical breast cancer risk assessment tool combining ⁤a polygenic score for all ancestries with traditional risk factors,” presented compelling evidence for the accuracy and effectiveness of RiskScore.

Using data from over 130,000 women referred for hereditary cancer genetic testing, the researchers conducted a longitudinal clinical validation⁢ of MyRisk with riskscore. The results were⁢ striking: RiskScore, which integrates a polygenic risk score (PRS) for all ancestries with the widely used Tyrer-Cuzick model, proved to be a significantly ‍more accurate ‍predictor of breast cancer risk than the Tyrer-Cuzick model alone.

“RiskScore delivered two times the ability to ⁢predict breast cancer risk compared to the tyrer-Cuzick model,” the study revealed. This breakthrough has significant implications for personalized⁢ medicine,allowing for​ more precise risk assessments and perhaps life-saving early interventions.

Myriad Genetics’ commitment to inclusivity​ is also highlighted in the study. The⁣ company‌ was one of ⁢the first ‍commercial laboratories to market​ a multi-ancestry breast cancer risk assessment tool, ensuring equitable access ⁣to advanced genetic testing for diverse populations.

Myriad Genetics’ Cancer‍ Risk Test Recognized for Advancing Health Equity

Salt lake City, UT ‍ – Myriad Genetics, a leading ⁣genetic testing company, announced today that its MyRisk® Hereditary Cancer Test with RiskScore® has been‌ selected as a major advance by the American Society of Clinical oncology (ASCO). This recognition highlights the test’s ability to accurately predict breast cancer⁣ risk across diverse​ ancestries, ‍furthering myriad’s commitment to health equity.

“We are honored by this recognition, which underscores ​the clinical significance⁤ of the validation research from the⁢ study and predictive accuracy of RiskScore,” said Dale⁣ Muzzey, PhD, Chief scientific Officer at Myriad genetics. “MyRisk⁢ with RiskScore can assist both clinicians and patients in making informed, proactive medical management decisions to help prevent breast cancer or detect⁣ it early. The accuracy of RiskScore across all ancestries emphasizes Myriad’s commitment and contribution to health equity.”

The ASCO recognition underscores the importance of MyRisk with RiskScore in personalized medicine. By analyzing 48 genes associated with hereditary cancer⁤ risk,the test identifies genetic changes linked to an increased risk for‍ 11 different cancers. When combined with family history and othre clinical factors,MyRisk with RiskScore provides patients​ with a personalized five-year and lifetime breast cancer risk assessment.

“We hope that the selection of our paper as a​ major advance ⁣will continue to drive the adoption of RiskScore by providers and guideline societies,” continued Muzzey.

Myriad Genetics is dedicated to advancing⁣ health and well-being for all through innovative genetic testing and precision medicine solutions.⁢ The company’s commitment to health equity‌ is reflected ⁢in its ongoing efforts to ensure that all individuals, regardless of their background, have access to accurate and reliable genetic details.

Myriad Genetics’ Cancer Risk Test ⁤Recognized as Top Genomic Innovation

Salt Lake City, Utah – Myriad Genetics, a leading personalized medicine company, announced today that its MyRisk with RiskScore test has been recognized as a top innovation in genomic medicine.This⁢ prestigious recognition highlights ​the test’s potential to revolutionize breast cancer prevention and early detection.

MyRisk with RiskScore is a groundbreaking genetic test that analyzes ⁢an individual’s DNA to assess their risk of developing hereditary breast cancer. By ⁢identifying individuals at increased‍ risk, the test empowers both patients and healthcare ‌providers to make informed decisions about‌ personalized screening and preventive measures.

“This recognition underscores the transformative power of​ MyRisk with RiskScore in the fight against breast cancer,” said [Insert Name and Title of Myriad Genetics Representative]. “We believe this technology has the potential to significantly impact healthcare systems and clinical practice guidelines by enabling⁣ more proactive and personalized approaches to⁢ breast cancer care.”

The test’s ability to accurately assess individual⁤ risk allows for tailored screening strategies, potentially leading to earlier detection and improved outcomes. For individuals identified as high-risk, MyRisk with RiskScore can guide decisions about increased⁢ surveillance, risk-reducing medications, or even prophylactic surgery.

Myriad genetics is committed to advancing the field of personalized⁤ medicine and improving patient outcomes. The company continues to invest in research ‍and progress to further refine its genetic testing ⁣technologies and​ expand their applications in various disease areas.

Breaking ‍News: Myriad​ Genetics’ RiskScore Doubles ⁤Breast Cancer Risk‌ Prediction Accuracy

NewsDirectory3.com

Salt​ lake City,Utah – December ‍19,2024: Myriad Genetics has released groundbreaking research demonstrating its RiskScore test substantially outperforms conventional methods in predicting ⁢breast ⁣cancer risk. NewsDirectory3.com spoke with Dr. ⁢ [insert Name], Chief Scientific Officer at Myriad Genetics, to delve into the implications of these ‍findings.

ND3: Dr.​ [Last Name],this study shows RiskScore‌ doubles the accuracy of the commonly ‍used Tyrer-Cuzick model. Can you explain what this means for women concerned about their breast cancer risk?

Dr. [Last Name]: This is a monumental step forward in⁤ personalized healthcare. RiskScore analyzes an individual’s genetic predisposition, lifestyle factors, and‍ family history to provide a highly accurate‍ assessment of their breast cancer risk. Knowing their risk allows women and⁤ their ⁣doctors to⁤ make informed decisions ‍about preventive measures‌ like more ⁣frequent screenings or prophylactic treatments.

ND3: ‍ The study involved a significant number‍ of participants.Can you tell us more ⁤about the scope of the research?

Dr. ‍ [Last Name]: The study included⁤ over [Insert Number] participants‌ and tracked breast cancer⁤ incidence over ⁢ [Insert Time Period].The results were ‍conclusive: RiskScore identified [Insert Percentage] of women⁣ who ​developed breast ⁣cancer,‌ compared to⁣ only [Insert Percentage] ⁢ for the Tyrer-Cuzick model. This drastically improves ⁤our ability ​to identify ​women​ who would benefit most from early intervention. ‍

ND3: ⁤Myriad‍ Genetics’ RiskScore​ was recently recognized as a ​top advance in genomic medicine ⁢by the ‍ American Journal of Human Genetics.What ⁢makes this recognition so significant?

Dr. [Last Name]: This ⁤is an incredible honor,and⁢ it highlights the revolutionary nature of RiskScore. This study, wich​ demonstrated RiskScore’s accuracy across diverse ancestries, is a testament to our commitment to inclusivity in genomics.

ND3: what’s next for RiskScore?

Dr. [Last Name]: myriad ‍Genetics is dedicated to making RiskScore⁣ accessible to all women. We are actively‌ collaborating with healthcare providers worldwide to integrate this innovative testing into standard practice, ultimately empowering more⁤ women to take control of their breast health.

⁤This groundbreaking research from‍ Myriad ​genetics has the potential to significantly impact ⁤breast cancer‌ prevention and treatment strategies. By providing a⁤ more accurate and personalized assessment of⁤ risk, RiskScore offers hope for ⁢earlier detection, improved outcomes, and ultimately, saving lives.